Summit’s dual-acting drug scores lung cancer win

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.

By Jonathan Gardner • Oct. 20, 2025

Exelixis shares dip on colorectal cancer data

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

By Jacob Bell • Oct. 20, 2025

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

Roche pill delays tumor progression in closely watched breast cancer study

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar hormone-degrading drugs for breast tumors.

By Jonathan Gardner • Oct. 18, 2025

J&J claims success in study testing earlier Tecvayli use in multiple myeloma

The result marks a potential advance for dual-targeting antibody drugs like Tecvayli, which are currently relegated to later-line settings for the persistent blood cancer.

By Jonathan Gardner • Oct. 16, 2025

Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials. 

By Kristin Jensen • Oct. 15, 2025

[Podcast] The Progress Profile: Alzheimer’s Research in Focus

Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

By BioPharma Dive's studioID • Oct. 15, 2025

Kailera nets $600M more to advance Zepbound-like obesity drug

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that just succeeded in late-stage testing in China.

By Jonathan Gardner • Oct. 14, 2025

Maximizing biomarker insights from minimal samples

Unlock value with optimized workflows and scalable technologies.

Oct. 13, 2025

Pharma’s real-world data dilemma: Strategic asset or wasted resource?

To maximize RWD’s potential, pharma companies should begin with their business or clinical goals.

By Ilan Behm, VP, Real-World Data Engagement, Norstella and Ted Search, General Manager, Real-World Data, Norstella • Oct. 13, 2025

Regeneron, with ‘game-changing’ new data, to seek approval of hearing loss gene therapy

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a dozen children with a rare, genetic form of deafness.

By Jacob Bell • Oct. 12, 2025

AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer

The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.

By Delilah Alvarado • Oct. 6, 2025

Skye shares crash as obesity drug falls short in key study

The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to boost the effects of incretin therapies like Wegovy.

By Ben Fidler • Oct. 6, 2025

The advantage of engaging patient recruitment partners as strategic allies, not emergency backups

The secret to on-time trials? Engaging recruitment partners early.

By Ryan Day and Steve Wimmer • Oct. 6, 2025

Amgen claims ‘landmark’ study result that could widen heart drug’s use

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population. 

By Jonathan Gardner • Oct. 2, 2025

Metsera strengthens case for Pfizer buyout with latest study data

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.

By Jonathan Gardner • Sept. 30, 2025

Moonlake shares crash on mixed study results for immune drug

Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and “undifferentiated,” erasing more than four-fifths of the company’s market value.

By Ben Fidler • Sept. 29, 2025

Lilly stops trial of muscle-sparing obesity drug

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines. 

By Jonathan Gardner • Sept. 25, 2025

Cancer patients are living longer than ever. Pain drugmakers haven’t kept up.

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily pain. Doctors fear that’s bound to continue.

By Jacob Bell • Sept. 25, 2025

UniQure to seek approval of Huntington’s gene therapy after trial win

New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have “massive effects on patients’ lives,” an investigator said.

By Jonathan Gardner • Sept. 24, 2025

Acadia to scrap Prader-Willi drug after study setback

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential competitor to Soleno’s fast-selling Vykat. 

By Kristin Jensen • Sept. 24, 2025

Bristol Myers says next-gen blood cancer drug hits goal in key study

The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.

By Jonathan Gardner • Sept. 23, 2025

Meet the new EmVenio – where science meets people

EmVenio makes clinical trial participation easier, more inclusive and more reflective of our world.

By EmVenio Clinical Research • Sept. 22, 2025

Roivant pill succeeds in rare inflammatory disease trial

A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.

By Jonathan Gardner • Sept. 17, 2025

ATyr shares plunge on trial miss in inflammatory lung disease

The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.

By Jonathan Gardner • Sept. 15, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology

Early academic research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 12, 2025